Deep learning models can improve low-field MRI images for better clinical diagnoses

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more. Pfiz­er is lay­ing off em­ploy­ees across

The crown jew­el from Bay­er’s 2020 buy­out of women’s health biotech KaNDy Ther­a­peu­tics has proven its worth in the clin­ic, meet­ing all pri­ma­ry and sec­ondary